Literature DB >> 29273483

Growth hormone receptor (GHR) gene polymorphism and scoliosis in Prader-Willi syndrome.

Merlin G Butler1, Waheeda Hossain2, Maaz Hassan2, Ann M Manzardo2.   

Abstract

OBJECTIVE: A growth hormone receptor (GHR) gene polymorphism impacts sensitivity to endogenous and exogenous growth hormone (GH) to moderate growth and development. Increased sensitivity may accelerate spinal growth and contribute to scoliosis, particularly in GH-deficient and treated populations such as Prader-Willi syndrome (PWS). Therefore, we examined the relationship between GHR genotype and scoliosis (case and control) in PWS cohorts.
DESIGN: We utilized a case-control design in a study of 73 subjects (34M; 39F) with genetically confirmed PWS in 32 individuals previously diagnosed with moderate to severe scoliosis (mean age=16.9±10.2years; age range of 1 to 41years) and 41 adults with no evidence of scoliosis (mean age=30.8±9.7years; age range of 18 to 56years). The GHR gene polymorphism was determined using PCR specific primers to capture the two recognized GHR gene fragment sizes [i.e., full length (fl) or exon 3 deletions (d3)].
RESULTS: Twenty-three (72%) of the 32 case subjects with scoliosis required surgical correction with an approximately equal balance for gender and PWS genetic subtype among cases and 41 control subjects without scoliosis. The GHR d3/d3 genotype was identified in N=2 of 8 (25%) cases with scoliosis and the d3/fl genotype was identified in N=11 of 25 (44%) cases with scoliosis but the distribution difference did not statistically differ. The GHR fl/fl genotype was correlated with a significantly faster rate and heavier weight gain among case subjects.
CONCLUSION: Our examination of demographic and genetic markers associated with scoliosis and surgical repair in PWS found no evidence to support differences in gender, PWS genetic subtype or GHR d3 allele distributions among the case vs control groups. Those with fl/fl alleles were heavier than those with d3/d3 or d3/fl genotypes and warrant further study with a larger sample size and possibly to include other vulnerable populations requiring growth hormone treatment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GHR d3 allele; Growth hormone receptor (GHR) polymorphism; Growth hormone treatment; Prader-Willi syndrome (PWS); Scoliosis

Mesh:

Substances:

Year:  2017        PMID: 29273483      PMCID: PMC6668334          DOI: 10.1016/j.ghir.2017.12.001

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  22 in total

1.  The musculoskeletal manifestations of Prader-Willi syndrome.

Authors:  Jong Sup Shim; Sang Hak Lee; Sung Wook Seo; Kyung Hyo Koo; Dong Kyu Jin
Journal:  J Pediatr Orthop       Date:  2010-06       Impact factor: 2.324

2.  Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.

Authors:  A C Lindgren; E M Ritzén
Journal:  Acta Paediatr Suppl       Date:  1999-12

3.  Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.

Authors:  S E Myers; A L Carrel; B Y Whitman; D B Allen
Journal:  J Pediatr       Date:  2000-07       Impact factor: 4.406

4.  Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.

Authors:  U Eiholzer; D l'Allemand; I van der Sluis; H Steinert; T Gasser; K Ellis
Journal:  Horm Res       Date:  2000

5.  Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.

Authors:  M Tauber; C Barbeau; B Jouret; C Pienkowski; P Malzac; A Moncla; P Rochiccioli
Journal:  Horm Res       Date:  2000

6.  Changing rates of genetic subtypes of Prader-Willi syndrome in the UK.

Authors:  Joyce E Whittington; Jill V Butler; Anthony J Holland
Journal:  Eur J Hum Genet       Date:  2006-09-06       Impact factor: 4.246

7.  Complications of scoliosis surgery in Prader-Willi syndrome.

Authors:  Franck Accadbled; Thierry Odent; Alexandre Moine; Edouard Chau; Christophe Glorion; Gwenaelle Diene; Jérôme Sales de Gauzy
Journal:  Spine (Phila Pa 1976)       Date:  2008-02-15       Impact factor: 3.468

8.  A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone.

Authors:  Christine Dos Santos; Laurent Essioux; Cécile Teinturier; Maïté Tauber; Vincent Goffin; Pierre Bougnères
Journal:  Nat Genet       Date:  2004-06-20       Impact factor: 38.330

9.  Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.

Authors:  Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

10.  The growth hormone receptor gene deleted for exon three (GHRd3) polymorphism is associated with birth and placental weight.

Authors:  Raja Padidela; Sinead M Bryan; Sayeda Abu-Amero; Rebecca E Hudson-Davies; John C Achermann; Gudrun E Moore; Peter C Hindmarsh
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

View more
  2 in total

Review 1.  Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update.

Authors:  Merlin G Butler; Jennifer L Miller; Janice L Forster
Journal:  Curr Pediatr Rev       Date:  2019

Review 2.  Clinical Observations and Treatment Approaches for Scoliosis in Prader-Willi Syndrome.

Authors:  Harold J P van Bosse; Merlin G Butler
Journal:  Genes (Basel)       Date:  2020-02-28       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.